IMAP France advises BIOGROUP on the acquisition of Dyomedea-Neolab
Majority-owned by biologists, Dyomedea-Neolab is a major player in medical lab testing in the Auvergne-Rhône-Alpes region.
IMAP is pleased to announce that BIOGROUP has acquired Dyomedea-Neolab.
Majority-owned by biologists, Dyomedea-Neolab is a major player in medical lab testing in the Auvergne-Rhône-Alpes region. Operating 43 laboratories, mainly in the Rhône department, it generated revenues of€55 million in 2019.
BIOGROUP, which is majority-owned by Doctor Stéphane Eimer, operates over 710 labs located throughout France. The Group is the leading player in medical lab testing in France, with a pro-forma revenue of €930 million in 2019. The Group employs over 7,000 people, of which 790 are biologists.
By integrating Dyomedea-Neolab into its existing Unilians laboratory network, BIOGROUP's subsidiary in the Auvergne-Rhône-Alpes region, BIOGROUP is able to consolidate its leading position in the region. For Dyomedea-Neolab, being acquired by the French leader in medical lab testing, will enable it to pursue its investment policy for medical innovation and strengthen its regional presence.
The IMAP France (Degroof Petercam) team, led by Cyril Kammoun, acted as exclusive financial advisor to BIOGROUP. Since January 2020, this is the 6th transaction in the medical lab testing industry for the team, which has established itself as the leading player in M&A advisory and financing in this sector.